Tokyo, Aug. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062605) titled 'Concordance analysis between HER2 immunohistochemistry and next generation sequencer in non-small lung cancer' on Aug. 19.
Study Type:
Observational
Primary Sponsor:
Institute - not applicable
Condition:
Condition - non-small lung cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To establish a HER2 screening system, we analysis HER2 overexpression by IHC in HER2 amplified NSCLC.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Recurrent or progre...